Related Experiment Video

Updated: Mar 11, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.9K

[Cardiovascular morbidity and mortality in patients with kidney disease]

Ivo Quack, Ralf Westenfeld

    Deutsche Medizinische Wochenschrift (1946)
    |December 1, 2016
    PubMed

    Insights

    Patients with kidney disease face higher cardiovascular risks. New SGLT2 inhibitors and GLP1 agonists show promise, while device therapies require careful consideration for hemodialysis patients.

    Area of Science:

    • Nephrology
    • Cardiology
    • Pharmacology

    Background:

    • Patients with chronic kidney disease (CKD) exhibit significantly increased cardiovascular morbidity and mortality.
    • Diabetic individuals with renal insufficiency face a heightened risk of cardiovascular events.
    • Sudden cardiac death in CKD patients is often linked to bradycardia and asystole.

    Purpose of the Study:

    • To review current therapeutic strategies for cardiovascular risk reduction in patients with kidney disease.
    • To evaluate the efficacy of specific pharmacological agents and device therapies in this high-risk population.
    • To discuss the implications of recent findings for clinical practice and future research.

    Main Methods:

    • Review of recent clinical studies and registry data concerning cardiovascular outcomes in CKD patients.
    • Analysis of the impact of SGLT2 inhibitors (Empagliflozin) and GLP1 agonists (Liraglutide) on cardiovascular risk.
    • Evaluation of the role of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) in CKD patients.
    • Assessment of the effectiveness of drug-eluting stents versus bare metal stents in patients with CKD.

    Main Results:

    • Empagliflozin and Liraglutide demonstrate potential in lowering cardiovascular risk in type 2 diabetics with renal insufficiency.
    • Registry data do not support the benefit of ICDs in hemodialysis patients.
    • Everolimus-eluting stents show superior outcomes compared to bare metal stents in CKD patients, with registry data indicating a survival benefit for drug-eluting stents.
    • The role of CRT in slowing cardiomyopathy in CKD requires further prospective investigation.

    Conclusions:

    • Pharmacological interventions like SGLT2 inhibitors and GLP1 agonists offer promising cardiovascular risk reduction in CKD patients.
    • Device therapy implementation in hemodialysis patients necessitates a personalized approach, balancing guideline indications with individual risk and life expectancy.
    • Drug-eluting stents are recommended over bare metal stents for patients with CKD undergoing percutaneous coronary intervention.

    More Related Videos

    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

    Published on: November 7, 2017

    22.3K
    5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

    5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

    Published on: April 4, 2025

    1.9K

    Related Concept Videos

    Chronic Kidney Disease II: Clinical Manifestations01:24

    Chronic Kidney Disease II: Clinical Manifestations

    Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
    864
    Chronic Kidney Disease IV: Nursing Management01:18

    Chronic Kidney Disease IV: Nursing Management

    Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
    518
    Chronic Kidney Disease I: Introduction01:25

    Chronic Kidney Disease I: Introduction

    Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
    931
    Chronic Kidney Disease III: Interprofessional Care01:28

    Chronic Kidney Disease III: Interprofessional Care

    Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
    565
    Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

    Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

    Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
    285
    Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

    Acute Kidney Injury IV: Diagnostic Studies and Prevention

    Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
    437